Oregon Mesothelioma Fact Sheet
While mesothelioma is a problem in all states, the specific incident rate for Oregon is 1.2 / 100,000. This is above the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in OR, recent OR mesothelioma-related court cases, mesothelioma specialists in OR and potential asbestos hotspots in Oregon.
Oregon Mesothelioma Info
By clicking on the above tabs, you will find information on mesothelioma specific to the state of Oregon
Oregon Research and Clinical Trials
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Oregon Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Oregon Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Oregon Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Oregon Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
Mason v. Mt. St. Joseph, Inc.
A133639, COURT OF APPEALS OF OREGON, March 13, 2008, Argued And Submitted, March 4, 2009, Filed
A133639, COURT OF APPEALS OF OREGON, March 13, 2008, Argued And Submitted, March 4, 2009, Filed
Dahlke v. Cascade Acoustics, Inc.
A127280, COURT OF APPEALS OF OREGON, June 13, 2007, Argued And Submitted, November 7, 2007, Filed
A127280, COURT OF APPEALS OF OREGON, June 13, 2007, Argued And Submitted, November 7, 2007, Filed
Union Bank of Cal., N.A. v. Copeland Lumber Yards, Inc.
A131135, COURT OF APPEALS OF OREGON, February 21, 2007, Argued And Submitted, Banks High School, Banks. , June 13, 2007, Filed
A131135, COURT OF APPEALS OF OREGON, February 21, 2007, Argued And Submitted, Banks High School, Banks. , June 13, 2007, Filed
Solberg v. Tice Elec. (In re Solberg)
A129565, COURT OF APPEALS OF OREGON, December 21, 2006, Argued And Submitted, May 2, 2007, Filed
A129565, COURT OF APPEALS OF OREGON, December 21, 2006, Argued And Submitted, May 2, 2007, Filed
Weihl v. Asbestos Corp., Ltd.
A122068 , COURT OF APPEALS OF OREGON, June 6, 2005, Argued And Submitted , February 15, 2006, Filed
A122068 , COURT OF APPEALS OF OREGON, June 6, 2005, Argued And Submitted , February 15, 2006, Filed
West v. Allied Signal, Inc.
A122831 , COURT OF APPEALS OF OREGON, March 31, 2005, Argued And Submitted , June 15, 2005, Filed
A122831 , COURT OF APPEALS OF OREGON, March 31, 2005, Argued And Submitted , June 15, 2005, Filed
Hospitals and Cancer Centers
We do not have any doctors or cancer centers for this state at the moment.
We do not have any doctors or cancer centers for this state at the moment.
| City | Site |
| Arrosport |
International Paper Company |
| Astoria |
Astoria Naval Shipyard Astoria Oil Services |
| Dawbend |
Northwest Boiler Inc. |
| Deer Island |
Shell Chemical Fertilizer |
| Dillard |
Roseburg Lumber |
| Newberg |
Publishers Paper Mill |
| Oregon City |
Publishers Paper Mill |
| Portland |
Dillingham Shipyard Gunderson Shipyard Kaiser Ship Repair Mobil Oil Marketing Plant Northwest Marine Northwest Marine Iron Works Pennwalt Chemical Plant Portland Court House Portland Ship Repair Yard Shell Oil Marketing Plant Tidewater Oil Marketing Plant |
| Portland |
Trojan Nuclear Plant |
| Portland |
US Bank Corp |
| Salem |
RC Weaver |
| St. Helens |
Boise Cascade Paper Mill |
| Wauna |
Crown Zellerbach Paper Mill |
| West Linn |
Crown Zellerbach |
Research
Fletcher, William S. Southwest Oncology Group
Grant: 2U10CA046113-06
Grant: 2U10CA046113-06
Abstract: The specific purpose of this application is to obtain continued funding
to support a multi-disciplinary program to conduct clinical research with
cancer patients through participation in the Southwest Oncology Group
(SWOG). This approach to cancer management is unique in this portion of
the Pacific Northwest and provides contemporary treatment alternatives to
an otherwise relatively isolated population.
Specifically, the program proposes to:
1. Combine the disciplines of Surgical, Medical, and Radiation Oncology,
Pathology, Immunology and Nursing Oncology in a synergistic attack on
clinical cancer management by participation in SWOG protocols.
2. Participate in SWOG Phase II, III, and adjuvant studies.
3. Develop and conduct pre-clinical and clinical pilot studies for
possible use by the SWOG. Such studies will include, but are not limited
to, the neuroendocrine control of breast and prostatic cancer, regional
chemotherapy by perfusion, infusion, and chemoembolization, suppression
of functioning tumors of the gastrointestinal tract and other cancers by
the synthetic somatostatin (Octreotide), multiple modality therapy in the
treatment of tumors such as alveolar soft part sarcoma metastatic to
lung, retroperitoneal sarcomas and mesothelioma of the pleura, and the
genetics of hematopoietic growth factors.
4. Provide core laboratory support and suitable administrative facilities
for the clinical evaluation of various techniques for the neuroendocrine
control of cancer.
5. To modernize data entry and management capabilities by computerization
as this capability develops within SWOG.
6. Further define chemosenstivity testing for determination of drug and
hormone sensitivity in solid tumors.
7. To return SWOG information and expertise to the local area by
consultation, lecture and symposia for the benefit of regional physicians
and patients.
Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Surgery Breast Neoplasm, Cancer Registry /resource, Clinical Study /trial, Colon Neoplasm, Computer Data Analysis, Cooperative Study, Gastrointestinal Neoplasm, Health Care Referral /consultation, Hematopoietic Growth Factor, Hormone Therapy, Human Therapy Evaluation, Immunomodulator, Intraarterial Administration, Meeting /conference /symposium, Melanoma, Mesothelioma, Metastasis, Neoplasm /cancer Remission /regression, Neuroendocrine System, Pancreas Neoplasm, Perfusion, Peritoneum Neoplasm, Pleural Neoplasm, Prostate Neoplasm, Sarcoma, Somatostatin Cancer Information System, Human Subject
Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Surgery Breast Neoplasm, Cancer Registry /resource, Clinical Study /trial, Colon Neoplasm, Computer Data Analysis, Cooperative Study, Gastrointestinal Neoplasm, Health Care Referral /consultation, Hematopoietic Growth Factor, Hormone Therapy, Human Therapy Evaluation, Immunomodulator, Intraarterial Administration, Meeting /conference /symposium, Melanoma, Mesothelioma, Metastasis, Neoplasm /cancer Remission /regression, Neuroendocrine System, Pancreas Neoplasm, Perfusion, Peritoneum Neoplasm, Pleural Neoplasm, Prostate Neoplasm, Sarcoma, Somatostatin Cancer Information System, Human Subject
- Followup Grant: 5U10CA046113-07
- Followup Grant: 5U10CA046113-08
- Followup Grant: 5U10CA046113-10
- Followup Grant: 2U10CA046113-11
- Followup Grant: 5U10CA046113-12
- Followup Grant: 5U10CA046113-14
- Followup Grant: 5U10CA046113-15
- Followup Grant: 5U10CA046113-16
Bright, Robert K. T Cell Focused Cancer Vaccines In Murine Tumor Models
Grant: 7R29CA077351-03
Grant: 7R29CA077351-03
Abstract: DESCRIPTION: (Applicant's Abstract) One in six people will die of cancer.
the systemic nature, recall ability and exquisite specificity of the immune
system makes immunotherapy an attractive prospect for cancer treatment.
Hepatocellular carcinoma, cervical carcinoma, various leukemias and
lymphomas all have proposed viral etiologies. Viral encoded tumor specific
antigens make viral associated tumors strong candidates for immunotherapy.
Recent studies have described the presence of simian virus 40 (SV40)-like
gene sequences and proteins (specifically the large tumor antigen: SV40
Tag) in human osteosarcomas, glioblastomas, ependymomas and malignant
pleural mesotheliomas (MPM), demonstrating SV40 association with certain
human malignancies. To facilitate the development of human clinical
protocols for the immunotherapy of SV40 associated human malignancies, the
proposed study will employ an SV40 murine tumor system to evaluate the
efficacy of CTL transfer therapies and peptide based vaccines designed to
target an immune response to SV40 Tag expressing tumors in vivo. Briefly,
SV40 Tag specific CTL will be generated by immunization of Balb/c mice with
SV40 Tag gene constructs and the epitope specificity determined by using
selected H-2d restricted synthetic peptides representing potential CTL
epitopes on SV40 Tag. These CTL will be utilized to examine the ability of
adoptively transferred T cells to protect against tumor challenge in
syngeneic mice. Further, selected synthetic peptides will be examined for
the ability to actively induce protective tumor immunity in vivo.
Completion of this study will provide valuable information on the active
induction of tumor destructive immunity involving SV40 Tag-epitope specific
CTL in vivo. Moreover, the information generated using the murine SV40
tumor model will expedite the development of reagents and clinical trials
designed to examine SV40 Tag specific immunotherapies for SV40 associated
human malignancies.
Tags: Cytotoxic T Lymphocyte, Neoplasm /cancer Immunology, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Vaccine, Nonhuman Therapy Evaluation, Simian Virus 40, Tumor Antigen Mhc Class I Antigen, Astrocytoma, Disease Model, Drug Screening /evaluation, Ependymoma, Immunogenetics, Mesothelioma, Neoplastic Cell, Neoplastic Transformation, Osteosarcoma, Synthetic Peptide, Virus Antigen, Virus Genetics, Virus Protein, Virus Related Neoplasm /cancer Active Immunization, Laboratory Mouse
Tags: Cytotoxic T Lymphocyte, Neoplasm /cancer Immunology, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Vaccine, Nonhuman Therapy Evaluation, Simian Virus 40, Tumor Antigen Mhc Class I Antigen, Astrocytoma, Disease Model, Drug Screening /evaluation, Ependymoma, Immunogenetics, Mesothelioma, Neoplastic Cell, Neoplastic Transformation, Osteosarcoma, Synthetic Peptide, Virus Antigen, Virus Genetics, Virus Protein, Virus Related Neoplasm /cancer Active Immunization, Laboratory Mouse
- Followup Grant: 5R29CA077351-04
- Followup Grant: 5R29CA077351-05
Clinical Trials
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Have questions about mesothelioma?
If you want answers right now call our Mesothelioma Resource Specialist - Abby Palmer, MSW.
She takes calls throughout the day and early evening. Her number is: 619-261-7922.
She is not a doctor and does not provide medical advice.
DISCLAIMER: Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly Inc. All of the information provided on this website is for informational purposes only. Neither Cancer Monthly nor this website renders medical advice or professional services. The information provided by Abby Palmer or any other employee or contractor of Cancer Monthly, Inc. is not to be considered medical advice and is not intended to replace consultation with a qualified medical professional. You should consult a qualified health care provider for medical advice and answers to personal health questions. The responsibility of your disease management plan is with your treating physicians and you should only follow your treating physician’s advice. DO NOT change or modify your disease management plan on your own without consulting your treating physicians. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website. Some information may be out of date. The information on this website is intended to convey general information only. It should not be construed as legal advice or opinion. This website and its contents are not intended to create an attorney-client relationship. You should not act on or rely on any information on this website without seeking the advice of an attorney. You are encouraged to promptly speak to legal counsel to identify and protect your legal rights and any deadlines for filing a claim or lawsuit. People who request a free book may be called to verify their address and to introduce other mesothelioma resources that are available.